140 related articles for article (PubMed ID: 8611049)
1. [Current problems in development of new anticancer agents for new molecular targets].
Nishii K
Gan To Kagaku Ryoho; 1996 Jan; 23(2):211-8. PubMed ID: 8611049
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
Petty RD
Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
[No Abstract] [Full Text] [Related]
5. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
6. [Molecular-target drug].
Sone S; Yano S; Nishioka Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
[TBL] [Abstract][Full Text] [Related]
7. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
Kusaba H; Tamura T
Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
[TBL] [Abstract][Full Text] [Related]
8. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
9. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
10. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Wang H; Han H; Mousses S; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
[TBL] [Abstract][Full Text] [Related]
11. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
12. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
13. [New basis for development of anticancer drugs].
Danø K
Ugeskr Laeger; 2001 Jul; 163(27):3759-62. PubMed ID: 11466981
[TBL] [Abstract][Full Text] [Related]
14. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
Rixe O; Fojo T
Clin Cancer Res; 2007 Dec; 13(24):7280-7. PubMed ID: 18094408
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
16. [Preclinical studies for development of anti-cancer drugs: current and historical status and problems].
Okabe M; Kobayashi S; Hirata T; Nakano H; Ikegami J; Inoue K; Komuro T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():302-9. PubMed ID: 7986108
[TBL] [Abstract][Full Text] [Related]
17. [Problems associated with molecular targeted drugs for cancer].
Kawaishi M; Koizum F; Nishio K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1373-9. PubMed ID: 17033223
[TBL] [Abstract][Full Text] [Related]
18. New anticancer agents: in vitro and in vivo evaluation.
Zips D; Thames HD; Baumann M
In Vivo; 2005; 19(1):1-7. PubMed ID: 15796152
[TBL] [Abstract][Full Text] [Related]
19. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
20. Epigenome-derived drugs: recent advances and future perspectives.
Vogiatzi P; Aimola P; Scarano MI; Claudio PP
Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
